LivaNova (LIVN) vs. The Competition Financial Survey

LivaNova (NASDAQ:LIVN) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its competitors? We will compare LivaNova to similar businesses based on the strength of its dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

Institutional and Insider Ownership

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 0.3% of LivaNova shares are owned by company insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for LivaNova and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0	3	8	1	2.83
LivaNova Competitors	4264	10506	18254	825	2.46

LivaNova currently has a consensus target price of $95.67, suggesting a potential upside of 1.57%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 16.65%. Given LivaNova’s competitors higher possible upside, analysts clearly believe LivaNova has less favorable growth aspects than its competitors.

Profitability

This table compares LivaNova and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
LivaNova Competitors	-278.16%	-150.10%	-21.89%

Volatility and Risk

LivaNova has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, LivaNova’s competitors have a beta of 2.57, meaning that their average stock price is 157% more volatile than the S&P 500.

Valuation and Earnings

This table compares LivaNova and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
LivaNova	$1.39 billion	-$242.47 million	27.87
LivaNova Competitors	$1.89 billion	$138.79 million	11.33

LivaNova’s competitors have higher revenue and earnings than LivaNova. LivaNova is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

LivaNova beats its competitors on 8 of the 13 factors compared.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.